Relvar Ellipta


fluticasone furoate / vilanterol

This medicine is authorised for use in the European Union.


Relvar Ellipta is an inhaler for treating asthma and chronic obstructive pulmonary disease (COPD).

In asthma, it is used for regular treatment of patients from 12 years of age:

  • whose symptoms are not controlled with an inhaled corticosteroid and an inhaled short-acting beta-2 agonist;
  • whose symptoms are adequately controlled with both inhaled corticosteroids and a long-acting beta-2 agonist.

In COPD, it is used in adults who have flare-ups of the disease despite regular bronchodilator treatment (treatment to widen the airways).

Relvar Ellipta contains the active substances fluticasone furoate and vilanterol.

This EPAR was last updated on 04/09/2023

Authorisation details

Product details
Relvar Ellipta
Agency product number
Active substance
  • fluticasone furoate
  • vilanterol
International non-proprietary name (INN) or common name
  • fluticasone furoate
  • vilanterol
Therapeutic area (MeSH)
Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
GlaxoSmithKline (Ireland) Limited
Date of issue of marketing authorisation valid throughout the European Union
Contact address

12 Riverwalk
Citywest Business Campus
Dublin 24

Product information

06/07/2023 Relvar Ellipta - EMEA/H/C/002673 - WS2438/G

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Adrenergics and other drugs for obstructive airway diseases

Therapeutic indication

Asthma indication:

Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:

  • patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.
  • patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.

COPD indication:

Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite bronchodilator therapy.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
1 rating
1 rating
1 rating